IX BIOPHARMA LTD.
(Company Registration Number 200405621W)
(Incorporated in the Republic of Singapore)

PROPOSED PLACEMENT TO RAISE GROSS PROCEEDS OF NO LESS THAN S$14,000,000 – RESULTS OF PROPOSED PLACEMENT

---

1. INTRODUCTION

1.1. The Board of Directors of iX Biopharma Ltd. (the "**Company**" and together with its subsidiaries, the "**Group**") (the "**Board**" or the "**Directors**") refers to its replacement announcement dated 25 November 2026 in relation to the entry into a placement agreement with Oversea-Chinese Banking Corporation Limited ("**Launch Announcement**").

1.2. Unless otherwise defined, all capitalised terms used herein shall have the same meaning as ascribed to them in the Launch Announcement.

1.3. Further to the Launch Announcement, the Company wishes to announce that the Placement Agent, in consultation with the Company, has closed the book of orders for the Proposed Placement on 25 November 2026.

1.4. The Board is also pleased to announce that the Proposed Placement received strong investor demand, reflecting investor recognition of the Group's growth momentum and prospects. In response, the Company and the Placement Agent have entered into an upsize option supplement to increase the number of New Shares to be issued under the Proposed Placement, raising additional gross proceeds of approximately S$1.24 million. Accordingly, a total of 38,291,000 New Shares will be issued at the Placement Price, thus increasing the aggregate gross proceeds to S$15,239,818. This represents an increase of approximately 9% over the minimum gross proceeds of S$14,000,000 previously announced in the Launch Announcement.

1.5. The 38,291,000 New Shares represent approximately 3.49% of the existing issued and paid-up share capital of the Company comprising 1,095,998,253 Shares ("**Existing Share Capital**") as at the date of this announcement, and will represent approximately 3.38% of the enlarged issued and paid-up share capital of the Company comprising 1,134,289,253 Shares (assuming there are no changes to the number of Shares from the date of this announcement to the date of Completion) ("**Enlarged Share Capital**"). The Company does not have any treasury shares or subsidiary holdings.

2. USE OF PROCEEDS

2.1. Further to the Launch Announcement and in view of the additional gross proceeds raised, the Company wishes to update shareholders that it intends to apply the Net Proceeds from the Proposed Placement in the following estimated proportions:

Proposed use of Net Proceeds	**% of the Net Proceeds from the Proposed Placement**
Development of the Group's consumer and compounding business, including potential strategic investments, acquisitions and/or partnerships	50%
Development and commercialisation of Wafermine	17%
General working capital	33%
Total	**100%**

2.2. Pending the deployment of the Net Proceeds (being the gross proceeds after deduction of fees and expenses incurred in connection with the Proposed Placement of approximately S$599,000), such Net Proceeds may be deposited with banks or financial institutions, invested in short-term money market instruments or marketable securities, and/or used for any other purpose on a short-term basis, as the Company may, in its absolute discretion, deem fit from time to time.

2.3. The Company will make periodic announcement(s) as to the use of the Net Proceeds as and when such proceeds are materially disbursed and whether such use is in accordance with the stated use. The Company will also provide a status report on the use of the Net Proceeds in the Company's interim and full-year financial statements issued under Rule 705 of the Catalist Rules and the Company's annual reports. Where the Net Proceeds have been used for working capital purposes, the Company will provide a breakdown with specific details on how the Net Proceeds have been applied in the announcements and status reports. Where there is any material deviation from the stated use of the Net Proceeds, the Company will announce the reasons for such deviation.

3. MANDATE FOR THE ISSUANCE OF THE NEW SHARES

3.1. As set out in the Launch Announcement, the New Shares will be allotted and issued pursuant to the General Mandate granted by the shareholders of the Company at the 2026 AGM. Pursuant to the General Mandate, the Company may issue up to 547,999,126 Shares other than on a *pro rata* basis.

3.2. As at the date of this announcement, the Company has not issued any Shares under the General Mandate. Accordingly, the 38,291,000 New Shares (including 3,115,000 additional New Shares from the exercise of the upsize option supplement) to be issued pursuant to the Proposed Placement fall within the limits of the General Mandate.

4. ADDITIONAL LISTING APPLICATION

The Company will be applying to the SGX-ST, through its sponsor, UOB Kay Hian Private Limited, for the dealing in, listing of and quotation for the New Shares on the Catalist and will make the necessary announcement(s) upon receipt of the listing and quotation notice from SGX-ST.

5. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

Save as disclosed in the Launch Announcement and this announcement, none of the Directors or substantial shareholders of the Company or any of their respective associates has any interest, direct or indirect, in the Proposed Placement, other than through their respective shareholding interests in the Company (if any).

The Placement Agent has entered into the Placement Agreement with the Company and is a substantial shareholder of the Company. As of 24 November 2026, the Placement Agent has a deemed interest in an aggregate of 55,318,700 Shares held by BOS Trustee Limited ("**BOSTL**") and Lion Global Investors Limited ("**LGI**"). The Placement Agent's deemed interest represents 5.05% of the Existing Share Capital and 4.88% of the Enlarged Share Capital.

As of 24 November 2026, BOSTL has a deemed interest in 2,100,000 Shares of the Company held by Adeli Holdings Limited, the registered shareholder of such Shares. Adeli Holdings Limited is wholly owned by BOSTL in its capacity as trustee of the 2011 trust. BOSTL is a wholly owned subsidiary of Bank of Singapore Limited, which is, in turn, a wholly owned subsidiary of the Placement Agent.

As of 24 November 2026, LGI has a deemed interest in 53,218,700 Shares through a Private Mandate Portfolio and a Unit Trust Fund managed by LGI. LGI is jointly owned by Great Eastern Holdings Limited and Orient Holdings Pte Ltd. Orient Holdings Pte Ltd is a wholly

owned subsidiary of the Placement Agent, while Great Eastern Holdings Limited is a subsidiary of the Placement Agent.

6. FURTHER ANNOUNCEMENTS

The Company will continue to keep its shareholders updated and release announcements relating to the Proposed Placement (including any material developments and progress made) as may be appropriate from time to time.

7. RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Proposed Placement, the Company and its subsidiaries in relation to the Proposed Placement, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this announcement in its proper form and context.

8. CAUTIONARY STATEMENT

Shareholders and potential investors should note that the Proposed Placement is subject to the fulfilment of, *inter alia*, the conditions set out under the Placement Agreement. Accordingly, they should exercise caution when trading in the Shares of the Company. Persons who are in doubt as to the action they should take should consult their legal, financial, tax or other professional advisers.

By Order of the Board
IX BIOPHARMA LTD.

Eddy Lee Yip Hang
Chairman & CEO

25 November 2026

---

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.

IMPORTANT NOTICE

Notification under Section 309B of the Securities and Futures Act 2001 of Singapore: The New Shares are prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in the MAS

Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

The offer and sale of the New Shares is being made solely in Singapore and does not constitute an offer or sale in the United States or to U.S. persons. The Company is not relying on Regulation S under the United States Securities Act of 1933, as amended.